A Pivotal Randomized, Open –Label Study of Optune (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed GlioblastomaBrain Continue to A Pivotal Randomized, Open –Label Study of Optune (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozatinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGrEE]Bladder/Urothelial Continue to PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozatinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGrEE]
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene AlterationsBladder/Urothelial Continue to A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III StudyColorectal Continue to Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)Colorectal Continue to Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast CancerBreast Continue to Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase IIIBreast Continue to Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)Ovarian Continue to A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)Colorectal Continue to Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer(KEYNOTE-A18 / ENGOT-cx11)Cervical Continue to A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer(KEYNOTE-A18 / ENGOT-cx11)
A Phase III Randomized, Placebo – Controlled Study of Pembrolizumab (MK-3475, NSC #776864) IN Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVE or Recurrent Endometrial CancerEndometrial Continue to A Phase III Randomized, Placebo – Controlled Study of Pembrolizumab (MK-3475, NSC #776864) IN Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVE or Recurrent Endometrial Cancer
A Phase 2 Clinical Study of TJ004309 in Combination with Atezolizumab (TECENTRIQ(r)) in Patients with Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid TumorsOvarian Continue to A Phase 2 Clinical Study of TJ004309 in Combination with Atezolizumab (TECENTRIQ(r)) in Patients with Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. (AXLerate-OC)Ovarian Continue to A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. (AXLerate-OC)
A phase II, single arm study of Mirvetuximab Soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expressionOvarian Continue to A phase II, single arm study of Mirvetuximab Soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (PROFECTA-II)Ovarian Continue to An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (PROFECTA-II)
A Randomized Phase III Trial od Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLCLung Continue to A Randomized Phase III Trial od Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Versus Standard Chemotherapy in Patient with Previously Treated Non-Squamous NSCLCLung Continue to A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Versus Standard Chemotherapy in Patient with Previously Treated Non-Squamous NSCLC
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCCHead & Neck Continue to A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase 2b, Open-Label, Single-Arm, Multi-Center Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO)Uterine Continue to A Phase 2b, Open-Label, Single-Arm, Multi-Center Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO)
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung CancerLung Continue to Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC ALCHEMIST CHEMO-IOLung Continue to Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC ALCHEMIST CHEMO-IO
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)Lung Continue to Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Limited Stage Small Cell Lung Cancer (LS-SCLC): Phase II/III Randomized Study of Chemoradiation versus Chemoradiation Plus AtezolizumabLung Continue to Limited Stage Small Cell Lung Cancer (LS-SCLC): Phase II/III Randomized Study of Chemoradiation versus Chemoradiation Plus Atezolizumab
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology SettingMulti Site/Multi Disease Continue to Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
Duloxetine to Prevent Oxaliplatin – Induced Chemotherapy – Induced Peripheral Neuropathy: A Randomized, Double – Blind, Placebo – Controlled Phase II to Phase III StudyMulti Site/Multi Disease Continue to Duloxetine to Prevent Oxaliplatin – Induced Chemotherapy – Induced Peripheral Neuropathy: A Randomized, Double – Blind, Placebo – Controlled Phase II to Phase III Study
Molecular Analysis for Therapy Choice (MATCH)Multi Site/Multi Disease Continue to Molecular Analysis for Therapy Choice (MATCH)
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer PatientsMulti Site/Multi Disease Continue to Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients
Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)Prostate Continue to Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic CancerPancreatic Continue to A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment NaÏve Metastatic Pancreatic Cancer (GIANT)Pancreatic Continue to A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment NaÏve Metastatic Pancreatic Cancer (GIANT)
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)Observational Trials Continue to A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) For Low Risk DCIS: A Phase III Prospective Randomized TrialBreast Continue to Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) For Low Risk DCIS: A Phase III Prospective Randomized Trial
A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPancreatic Continue to A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Use of Clinical Trial Screening Selection Tool to Address Cancer Health Disparities in the NCI Community Oncology Research ProgramMulti Site/Multi Disease Continue to Use of Clinical Trial Screening Selection Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program
